Study shows proof of concept for sustained release with TAR-200

In this video, Siamak Daneshmand, MD, discusses the background and key findings from the study, “PENELOPE: Tissue Penetration Of Gemcitabine Phosphate Metabolites Following TAR-200 Administration vs Standard Intravesical Instillation In Minipigs,” which was presented at the Society of Urologic Oncology 25th Annual Meeting in Dallas, Texas. Daneshmand is a professor of urology and director of clinical research at the Keck School of Medicine of the University of Southern California, Los Angeles.

Video Transcript:

This is something we've known, but it's really nice to see it in print. This was a small study, 5 pigs—3 in one arm and 2 in the other. The 3 getting intravesical gemcitabine like usual, and the other 2 getting the TAR-200. The point of the study was to measure the tissue levels of the metabolites of gemcitabine at various time points. As expected, with the intravesical gemcitabine, what we've been using for many, many years, you see the high concentrations of the metabolites of gemcitabine within the tissue, but all of that goes away essentially within 24 hours. There's almost no detectable metabolites seen in the layers of the lamina propria and even the muscularis propria. Those are gone. But with the TAR-200 it's sustained up to 96 hours, which is what we've known. The whole premise of this intravesical gemcitabine releasing system is that you're going to see the sustained release, and you're seeing the tissue penetration of the metabolites, again, into both lamina propria as well as the muscle. So, small study, but a proof of concept that, yes, this is how it's working. It's the sustained release and constant exposure to the gemcitabine that's most likely responsible for the high efficacy rates of that we're seeing with the TAR-200 system.

This transcript was AI generated and edited by human editors for clarity.